Shanghai Haohai Biological Technology reports mid-year revenue and profit decline

Shanghai Haohai Biological Technology recorded a 7.48% decrease in revenue, totaling RMB1,292.64 million for the six months ended June 30, 2025, down from RMB1,397.11 million in the same period of 2024. Net profit attributable to ordinary equity holders also declined by 10.29% to RMB211.07 million, compared to RMB235.28 million in the prior year. Basic earnings per share for the period were RMB0.91, a decrease from RMB1.01 in 2024.

The company's R&D expenditure for the period was RMB98.40 million, a 21.53% reduction from RMB125.40 million in 2024, primarily due to several core R&D projects entering advanced clinical trial or registration phases. The overall gross profit margin remained stable at 70.11%. The board of directors declared an interim dividend of RMB0.40 (tax inclusive) per share for the six months ended June 30, 2025, consistent with the previous year.